These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10478274)

  • 1. Treatment and prevention of coronary heart disease by lowering serum cholesterol levels; from the pioneer work of C.D. de Langen to the third "Dutch Consensus on Cholesterol".
    Jukema JW; Simoons ML
    Acta Cardiol; 1999 Jun; 54(3):163-8. PubMed ID: 10478274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History of the cholesterol controversy in Britain.
    Thompson GR
    QJM; 2009 Feb; 102(2):81-6. PubMed ID: 19042967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lipid-lowering therapy in multiple risk factor management.
    Esper RJ
    Drugs; 1998; 56 Suppl 1():1-7; discussion 33. PubMed ID: 9740535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey.
    Reiner Ž; De Bacquer D; Kotseva K; Prugger C; De Backer G; Wood D;
    Atherosclerosis; 2013 Dec; 231(2):300-7. PubMed ID: 24267243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy?
    Montague T; Tsuyuki R; Burton J; Williams R; Dzavik V; Teo K
    Chest; 1994 Mar; 105(3):718-26. PubMed ID: 8131532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
    Yudkin JS
    BMJ; 1993 May; 306(6888):1313-8. PubMed ID: 8518573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations for secondary prevention of the clinical coronary cardiopathy].
    Rev Esp Cardiol; 1985; 38(1):14-20. PubMed ID: 2858911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.
    Krumholz HM; Seeman TE; Merrill SS; Mendes de Leon CF; Vaccarino V; Silverman DI; Tsukahara R; Ostfeld AM; Berkman LF
    JAMA; 1994 Nov; 272(17):1335-40. PubMed ID: 7772105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of lowering serum cholesterol on coronary heart disease risk.
    Rossouw JE
    Med Clin North Am; 1994 Jan; 78(1):181-95. PubMed ID: 8283930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European and American recommendations for coronary heart disease prevention.
    Wood D
    Eur Heart J; 1998 Feb; 19 Suppl A():A12-9. PubMed ID: 9519337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
    Assmann G; Schulte H; Funke H; von Eckardstein A
    Eur Heart J; 1998 Oct; 19 Suppl M():M8-14. PubMed ID: 9821011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.